Theranica
Neuromodulation-based Patch for Migraine Relief
Company Overview
Snapshot
Founded in November 2015 by Shimon Eckhouse, Alon Ironi, Ronen Jashek, and Slava Barabash, Theranica operates with 51–200 employees. The company has raised a total of $88.1 million across 5 funding rounds from 10 investors. In August 2022, Theranica secured Series C funding, led by New Rhein Healthcare Investors.
Business overview
Theranica develops advanced, clinically proven, and affordable digital therapeutics for prevalent neurological pain diseases. The company's core product is Nerivio, a self-contained family of therapeutic patches and wearables controlled by smartphone applications. Nerivio Migra, specifically, provides migraine treatment through neuromodulation by attaching a wearable patch to the arm, adapting therapy treatments to everyday life. Theranica combines electrical neurostimulation and neuromuscular stimulation technologies with wireless communication and smartphone applications to deliver effective products for various medical problems, serving the Health Tech & Life Sciences sector.
Strategic signal
In September 2023, Theranica announced a new study indicating a meaningful impact of its Nerivio device from as early as two weeks. This signals strong clinical validation and potential for accelerated patient adoption, reinforcing the device's efficacy in the digital therapeutics market for migraine relief.
Log in to access full profile ›Company Intelligence Q&A
- What is Theranica's primary product?
- Theranica's primary product is Nerivio, a neuromodulation-based therapeutic patch designed for migraine relief. It is controlled by a smartphone application and provides treatment through electrical neurostimulation.
- When was Nerivio Migra granted FDA De Novo clearance?
- Nerivio Migra won FDA De Novo clearance for acute treatment of migraines in May 2019.
- Which investors participated in Theranica's Series C funding round?
- In August 2022, Theranica secured Series C funding, with New Rhein Healthcare Investors leading the round and LionBird also participating.
- Has Theranica's Nerivio device received a CE Mark for use in Europe?
- Yes, in September 2020, the Nerivio smartphone-controlled wearable for acute treatment of migraine was granted CE Mark for use in Europe.
- What was a significant recognition for Nerivio in 2019?
- In November 2019, Theranica's Nerivio was named in TIME's List of 100 Best Inventions of 2019.